Abstract
Despite the application of recommended guideline-driven therapies and optimal medical interventions, individuals with established cardiovascular disease remain susceptible to additional cardiovascular incidents, a phenomenon referred to as residual risk. Analyses of clinical trial data reveal significant residual cardiovascular risk in all treated patients, even in the setting of optimal LDL-C reduction, thus enforcing the need to revise the algorithms beyond focusing on LDL-C levels. We present a case that highlights the problem of residual risk upon well controlled LDL-C levels and provide insights for additional measures for residual risk reduction.
| Original language | English |
|---|---|
| Pages (from-to) | 724-728 |
| Number of pages | 5 |
| Journal | Israel Medical Association Journal |
| Volume | 26 |
| State | Published - Dec 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- anticoagulants
- glucagon-like peptide-1 receptor agonist (GLP1 RA)
- lipoprotein(a)
- low-density lipoprotein cholesterol (LDL-C)
- triglycerides
Fingerprint
Dive into the research topics of 'Recurrent Cardiovascular Events Despite Optimal LDL-Cholesterol Reduction: Therapeutic Challenges'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver